Transformed Lymphoma - 20/12/17

Doi : 10.1016/j.hoc.2016.07.012

Mary Ann Anderson, MBBS, FRACP, FRCPA ^a,^b,^⁎ , Piers Blombery, MBBS, FRACP, FRCPA ^c, John F. Seymour, MBBS, FRACP, PhD ^c,^d
^a Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville 3050, Australia
^b Department of Clinical Hematology and Bone Marrow Transplantation, The Royal Melbourne Hospital, Parkville 3050, Australia
^c Department of Haematology, Peter MacCallum Cancer Centre, Parkville 3050, Australia
^d Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Parkville, Australia

^∗Corresponding author. Cancer and Haematology Division, Walter and Eliza Hall Institute of Medical Research, Parkville 3050, Australia.Cancer and Haematology DivisionWalter and Eliza Hall Institute of Medical ResearchParkville3050Australia

Résumé

Transformed lymphoma is a complex syndrome that encompasses an array of different underlying low-grade lymphoproliferative conditions transforming into more aggressive disease as manifest by morphologic, clinical, and genetic features. Over the last decade, advances in chemoimmunotherapy have led to new options. Knowledge surrounding the genetic changes driving the process of transformation is leading to novel targeted therapies. This article focuses on the transformation of chronic lymphocytic leukemia and follicular lymphoma into diffuse large B-cell lymphoma.

Le texte complet de cet article est disponible en PDF.

Keywords : Indolent lymphoma, Transformed lymphoma, Genetic drivers